asenapine
Antipsychotic • Brands: Saphris, Secuado
Last reviewed: 2025-12-29
General information
- Class: Antipsychotic
- Common US brands: Saphris, Secuado
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2025-12-29
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Second-generation antipsychotic with antagonism at dopamine D2/D3 and serotonin 5-HT2A receptors; also blocks H1 and α1 receptors.
Metabolism & Half‑life
- Metabolism: UGT1A4, CYP1A2
- Half‑life: Single-dose mean 24 h; Steady-state mean 24 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- SAPHRIS (asenapine) prescribing information — DailyMed (2024)
- SECUADO (asenapine transdermal system) prescribing information — DailyMed (2024)
- The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia — American Psychiatric Association (2020)
- The CANMAT and ISBD Guidelines for the Management of Patients With Bipolar Disorder: 2021 Update — Bipolar Disorders (2021)
- Asenapine in the treatment of acute mania associated with bipolar I disorder: a randomized double-blind trial — Bipolar Disorders (2009)
- Asenapine review, part II: clinical efficacy, safety and tolerability — Expert Opinion on Drug Safety (2014)